Company intelligence / Profile preview

LifeSprout

Baltimore, Maryland, United Stateslifesproutbio.com ↗

Ownership: Private
Development stage: Other

Overview

LifeSprout has developed a proprietary Regenerative Matrix technology that mimics native soft tissue. Its lead product Lumina™, a next-generation dermal filler for nasolabial folds and other soft-tissue defects, met its primary endpoint in a pivotal European trial with good safety and non-inferiority to Restylane Defyne®. No serious adverse events related to the product were reported. The company has filed for CE Mark approval in Europe with anticipated decision by late 2025. Additional regenerative cell therapy programs using the RM platform are at earlier stages.

Therapeutic areas: DermatologyOther
Modalities: Device (Dermal filler)Biomimetic material-based therapyCell therapy
Industry: Biotech

Partnerships

Boyang Trading Co., Ltd. – exclusive licensee for Greater China region for Lumina™ dermal filler

Beyond the preview

Go deeper on LifeSprout.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LifeSprout.

Explore the full profile